Company intelligence / Profile preview
Amphera B.V.
's-Hertogenbosch, 's-Hertogenbosch , Noord-Brabant, Netherlandsamphera.nl ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Amphera’s lead product MesoPher has completed a randomized phase II/III trial in pleural mesothelioma. While the primary endpoint was not met for all patients, clinically meaningful benefit was observed in a significant subgroup with stable disease after chemotherapy. The therapy demonstrated an excellent safety profile and induced broad immune responses. Positive results have also been reported from a phase II study in resected pancreatic cancer.
- Therapeutic areas
- Oncology
- Modalities
- Dendritic cell therapyTherapeutic vaccines (autologous dendritic cells loaded with tumor lysate)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Amphera B.V..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amphera B.V..